[Infliximab treatment of peristomal pyoderma gangrenosum in ulcerative colitis].
Nybaek
Hanne
H
Jemec
Gregor B E
GB
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000473:pathology / Q000601:surgery*; D039021:Colonic Pouches / Q000009:adverse effects; D003125:Colostomy / Q000009:adverse effects; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D007081:Ileostomy / Q000009:adverse effects; D000069285:Infliximab; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000209:etiology; D014945:Wound Healing / Q000187:drug effects
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab